Schizophrenia Clinical Trials Pipeline Analysis: 60+ Companies are Working to Improve the Treatment Space | DelveInsight

Increase in Research and Development activities for advancements in anti-psychotic drugs, product launches, and approvals has increased the Schizophrenia market. An increase in the development of the number of clinical trials for the development of novel schizophrenia treatment and a rise in the number of industrial collaborations in drug development boost the market for schizophrenia.

LAS VEGAS, April 5, 2023 /PRNewswire/ -- DelveInsight's 'Schizophrenia Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline schizophrenia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the schizophrenia pipeline domain.

Key Takeaways from the Schizophrenia Pipeline Report

• DelveInsight's schizophrenia pipeline report depicts a robust space with 60+ active players working to develop 65+ pipeline therapies for schizophrenia treatment. 
• Key schizophrenia companies such as Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, Boehringer Ingelheim, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Alkermes, Inc. , Solvay Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc, Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc, Amneal Pharmaceuticals, LLC, Recognify Life Sciences, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen, LP, Delpor, Inc., Jiangsu Hansoh Pharmaceutical, Cerevel Therapeutics, LLC, Zogenix, Inc., Luye Pharma, Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, Autifony Therapeutics, Neumora Therapeutics, Adex Therapeutics, and others are evaluating new schizophrenia drugs to improve the treatment landscape.
• Promising schizophrenia pipeline therapies in various stages of development include Luvadaxistat, Olanzapine Hydrochloride, Ulotaront,  LYN-005, BI 425809, AVP 786, Xanomeline and Trospium Chloride Capsule, SEP-363856, CVL-231, LY2140023, RL-007, TAK-041, LY03010 156, ASP6981, TPN-672, MK-8189, Emraclidine, CY6463, HS-10380, Pomaglumetad methionil, Back up modulators, Research Program, M4 PAM, and others.
• In March 2023, Karuna Therapeutics announced positive topline results from its Phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium) in adults with schizophrenia. 
• In September 2022, Otsuka America Pharmaceutical, Inc., (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) acceptance of their New Drug Application (NDA) for aripiprazole 2-month, ready-to-use, long-acting injectable, a medication administered for the treatment of schizophrenia in adults and for maintenance monotherapy treatment of bipolar I disorder in adults.

Request a sample and discover the recent advances in schizophrenia drug treatment @ Schizophrenia Pipeline Report

The schizophrenia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage schizophrenia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the schizophrenia clinical trial landscape.

Schizophrenia Overview

Schizophrenia is a word that has been around for over a century, and it has always perplexed scientific communities. A chronic psychotic disorder, schizophrenia meddles with the patient's thoughts, interferes with a patient's social ability, and hampers cognitive development. The exact causes of schizophrenia are unknown. According to research, a combination of physical, genetic, psychological, and environmental factors can increase a person's risk of developing the condition. Some people are predisposed to schizophrenia, and a stressful or emotionally charged life event may set off a psychotic episode.

Schizophrenia symptoms include delusions, hallucinations, disorganized speech, trouble with thinking, and feeling of demotivation. It is a disorder with variable phenotypic expression and poorly understood, complex etiology, involving a major genetic contribution and environmental factors interacting with the genetic susceptibility. Schizophrenia is diagnosed by ruling out other mental health disorders and determining that symptoms are not caused by substance abuse, medication, or a medical condition. A physical exam, blood tests, screening, including CT scan and MRI, and psychiatric evaluation using the schizophrenia symptoms diagnosis scale (PANSS, CGI, SANS, etc.) may be used for the schizophrenia diagnosis.

The current pyramid of interventions in managing schizophrenia includes antipsychotic medications, the most commonly prescribed schizophrenia drugs, and thought to control symptoms by affecting the brain neurotransmitter dopamine. Even after symptoms have faded, schizophrenia requires lifetime therapy. Apart from schizophrenia medications, psychological counseling, and social support, cognitive behavioral therapy and electroconvulsive therapy (ECT) can be used to control the condition. Hospitalization may be required in some circumstances.

Find out more about drugs for schizophrenia @ New Schizophrenia Drugs 

A snapshot of the Schizophrenia Pipeline Drugs mentioned in the report:

Learn more about the emerging schizophrenia pipeline therapies @ Schizophrenia Clinical Trials

Schizophrenia Therapeutics Assessment

The schizophrenia pipeline report proffers an integral view of schizophrenia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the Schizophrenia Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Intravenous, Oral, Parenteral, Subcutaneous
• Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
• Therapeutics Assessment By Mechanism of Action: Serotonin 1A receptor agonists, Trace amine-associated receptor 1 agonists, D amino acid oxidase inhibitors, Soluble guanylyl cyclase agonists, Cytochrome P 450 enzyme system inhibitors, KATP channel inhibitors, NMDA receptor antagonists, Norepinephrine plasma membrane transport protein inhibitors, Serotonin plasma membrane transport protein inhibitors, Sigma-1 receptor agonists, Sodium channel antagonists, Muscarinic M4 receptor modulators, Metabotropic glutamate receptor 2 agonists, Metabotropic glutamate receptor 3 agonists
• Key Schizophrenia Companies: Otsuka Pharmaceutical Development & Commercialization, Inc., Gedeon Richter Ltd., Lyndra Therapeutics, Neurocrine Bioscience, Takeda Pharmaceutical Company, Memory Pharmaceuticals, Hoffmann-La Roche, Neurocrine Biosciences, Boehringer Ingelheim, Meiji Seika Pharma Co., Ltd., SK Life Science, Inc., Alkermes, Inc. , Solvay Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, SyneuRx International (Taiwan) Corp, BioXcel Therapeutics Inc, Cognitive Research Corporation, Amarex Clinical Research, Forum Pharmaceuticals Inc, Amneal Pharmaceuticals, LLC, Recognify Life Sciences, Accutest Research Laboratories (I) Pvt. Ltd., Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C, Janssen, LP, Delpor, Inc., Jiangsu Hansoh Pharmaceutical, Cerevel Therapeutics, LLC, Zogenix, Inc., Luye Pharma, Reviva Pharmaceuticals, Alkermes, Inc., Karuna Therapeutics, Autifony Therapeutics, Neumora Therapeutics, Adex Therapeutics, and others.
• Key Schizophrenia Pipeline Therapies: Luvadaxistat, Olanzapine Hydrochloride, Ulotaront,  LYN-005, BI 425809, AVP 786, Xanomeline and Trospium Chloride Capsule, SEP-363856, CVL-231, LY2140023, RL-007, TAK-041, LY03010 156, ASP6981, TPN-672, MK-8189, Emraclidine, CY6463, HS-10380, Pomaglumetad methionil, Back up modulators, Research Program, M4 PAM, and others.

Dive deep into rich insights for new drugs for schizophrenia treatment; visit @ Schizophrenia Medications

Table of Contents

For further information on the schizophrenia pipeline therapeutics, reach out @ Schizophrenia Drug Treatment

Related Reports

Schizophrenia Market

Schizophrenia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key schizophrenia companies, including Boehringer Ingelheim, Karuna Therapeutics, Acadia Pharmaceuticals, Reviva Pharmaceuticals, Sunivion, PsychoGenics, Otsuka Pharmaceuticals, among others.

Schizophrenia Epidemiology Forecast

Schizophrenia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and schizophrenia epidemiology trends.

Dementia Market

Dementia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dementia companies, including Hoffmann-La Roche, Forest Laboratories, Inc., Janssen Pharmaceuticals, Inc., Merck and Co., Inc., Novartis, among others.

Bipolar Depression Market

Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including  Intra-Cellular Therapies, Sunovion Pharmaceuticals, COMPASS Pathways, among others.

Post Traumatic Stress Disorder Pipeline

Post Traumatic Stress Disorder Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key post-traumatic stress disorder companies, including Aptinyx, Jazz Pharmaceuticals, Bionomics Limited, among others.

Epilepsy Market

Epilepsy Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key epilepsy companies, including Eisai Co.LTD., Alexza Pharmaceuticals, Xenon Pharmaceuticals, among others.

Other Trending Reports

Tay-sachs Disease Or Gm2 Gangliosidosis Market | Onycholysis Market | Diagnostic Imaging Equipment Market | Chemotherapy-induced Peripheral Neuropathy Market | Global Electrophysiology Devices Market | Anaphylaxis Market | Atherectomy Devices Market | Helicobacter Pylori Infections Market | Ophthalmic Imaging Equipment Market | Androgenetic Alopecia Market | Allergic Rhinitis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Colorectal Cancer Crc Market | Opioid Induced Constipation Market | Vertigo Market | Bone Anchored Hearing Systems Market | Wound Closure Devices Market | Hip Replacement Devices Market | Hemodynamic Monitoring Systems Market | Egfr Non-small Cell Lung Cancer Market | Helicobacter Pylori Infection Market | Hyperkalemia Market | Polycythemia Market Neurostimulation Devices Market | Carpal Tunnel Syndrome Market | Ventilator Market | Cerebral Aneurysm Market | Alpha Antitrypsin Market | Binge Eating Disorder Market | Bunion Market | Concussions Market Size | Exocrine Pancreatic Insufficiency Market | Healthcare Due Diligence Services | Minimal Residual Disease Market | Hypertrophic Scar Market | Lung Fibrosis Market | Anterior Uveitis Market | 22q11.2 deletion syndrome Market | X-Linked Retinitis Pigmentosa (XLRP) Market | Acute Radiation Syndrome Market | Alpha-1 Protease Inhibitor Deficiency Market | Androgenetic Alopecia Market | Hyperlipidemia Market | Cardiotoxicity Market | Hypertrophic Cardiomyopathy Market | Fatty Acid Oxidation Disorders (FAODs) Market | Androgen Insensitivity Syndrome Market | Emphysema Market | Canaloplasty Market | Dravet Syndrome Market | Celiac Disease Market | Chlamydia Infections Market | Syphilis Market | Renal Tubular Acidosis Market | Palmoplantar Pustulosis (PPP) Market | Aplastic Anemia Market | Bacterial Pneumonia Market | B cell Chronic Lymphocytic Leukemia Market | B cell Lymphomas Market | Behcets Disease Market Neoantigen-based Personalized Cancer therapeutic Vaccines Competitive Landscape and Market Forecast—by 2035 | Glioblastoma Market 

Related Healthcare Blogs

Telepyschiatry Market

Digital Therapeutics for Mental Health

Schizophrenia Treatment Market

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com 
+1(919)321-6187 
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP